MeeraSridharanMD

Hematologic Oncology

Physician

Dr. Sridharan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2015 - 2018
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 2012 - 2015
Saint Louis University School of MedicineClass of 2012

PubMed

5 citations
Shiga Toxin as a Potential Trigger of CFHR1 Deletion-Associated Thrombotic Microangiopathy
Swarna Sri Nalluru, Meera Sridharan, Ronald S. Go, Samar M. Said, Ariela L. Marshall
The American Journal of the Medical Sciences. 2018-11-01
16 citations
Race, rituximab, and relapse in TTP.
Shruti Chaturvedi, Ana G Antun, Andrew M Farland, Ryan Woods, Ara Metjian
Blood. 2022-09-22
25 citations
Diamide decreases deformability of rabbit erythrocytes and attenuates low oxygen tension-induced ATP release
Meera Sridharan, Randy S. Sprague, Shaquria P. Adderley, Elizabeth A. Bowles, Mary L. Ellsworth
Experimental Biology and Medicine. 2010-09-01

Abstracts/Posters

Differential Effect of Rituximab on Relapse-Free Survival in De Novo and Relapsed Immune Thrombotic Thrombocytopenic Purpura in African-American and Caucasian Populations
Meera Sridharan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
African American Race Is Associated with Decreased Relapse-Free Survival in Immune Thrombotic Thrombocytopenic Purpura
Meera Sridharan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Collaborative Study Discovers New Disease Behind Patient’s Blood ClotsApril 20th, 2023